Volume 25, Number 9—September 2019
Research
Effect of Pneumococcal Conjugate Vaccines on Pneumococcal Meningitis, England and Wales, July 1, 2000–June 30, 2016
Table 2
Association between Streptococcus pneumoniae serotype and meningitis (vs. nonmeningitis) by serotype ranking, England and Wales, July 1, 2011–June 30, 1016*
Serotype rank | Serotype | Total cases | Nonmeningitis cases, n = 20,800, no. (%) | Meningitis cases, n = 920, no. (%) | aOR (95% CI) | p value† |
---|---|---|---|---|---|---|
1 | 8 | 3,285 | 3,184 (15.3) | 101 (11.0) | 0.69 (0.56–0.86) | <0.001 |
2 | 12F | 1,809 | 1,729 (8.3) | 80 (8.7) | 0.99 (0.78–1.27) | 0.961 |
3 | 22F | 1,725 | 1,640 (7.9) | 85 (9.2) | 1.39 (1.1–1.76) | 0.006 |
4 | 3 | 1,598 | 1,542 (7.4) | 56 (6.1) | 0.99 (0.74–1.31) | 0.924 |
5 | 7F | 1,542 | 1,482 (7.1) | 60 (6.5) | 0.73 (0.56–0.96) | 0.026 |
6 | 19A | 1,485 | 1,446 (7.0) | 39 (4.2) | 0.62 (0.45–0.86) | 0.005 |
7 | 15A | 1,024 | 986 (4.7) | 38 (4.1) | 1.09 (0.78–1.54) | 0.603 |
8 | 9N | 954 | 928 (4.5) | 26 (2.8) | 0.77 (0.51–1.15) | 0.2 |
9 | 33F | 827 | 774 (3.7) | 53 (5.8) | 1.34 (0.99–1.81) | 0.057 |
10 | 1 | 602 | 588 (2.8) | 14 (1.5) | 0.33 (0.19–0.56) | <0.001 |
11 | 10A | 566 | 511 (2.5) | 55 (6.0) | 2.06 (1.52–2.79) | <0.001 |
12 | 23A | 548 | 523 (2.5) | 25 (2.7) | 1.51 (1–2.29) | 0.052 |
13 | 24F | 548 | 528 (2.5) | 20 (2.2) | 0.73 (0.46–1.16) | 0.187 |
14 | 6C | 514 | 497 (2.4) | 17 (1.8) | 0.95 (0.58–1.57) | 0.852 |
15 | 11A | 512 | 498 (2.4) | 14 (1.5) | 0.71 (0.41–1.23) | 0.221 |
16 | 23B | 499 | 462 (2.2) | 37 (4.0) | 1.73 (1.21–2.48) | 0.003 |
17 | 15B/C | 453 | 416 (2.0) | 37 (4.0) | 1.31 (0.91–1.89) | 0.146 |
18 | 16F | 418 | 408 (2.0) | 10 (1.1) | 0.77 (0.41–1.45) | 0.415 |
19 | 35F | 371 | 349 (1.7) | 22 (2.4) | 1.47 (0.93–2.32) | 0.096 |
20 | 35B | 334 | 308 (1.5) | 26 (2.8) | 2.12 (1.38–3.25) | <0.001 |
21 | 31 | 282 | 273 (1.3) | 9 (1.0) | 1.14 (0.58–2.25) | 0.703 |
22 | 20 | 240 | 235 (1.1) | 5 (0.5) | 0.46 (0.19–1.12) | 0.086 |
23 | 38 | 239 | 229 (1.1) | 10 (1.1) | 0.79 (0.41–1.54) | 0.49 |
24 | 17F | 235 | 221 (1.1) | 14 (1.5) | 1.71 (0.98–2.98) | 0.058 |
25 | 19F | 183 | 171 (0.8) | 12 (1.3) | 1.24 (0.68–2.28) | 0.483 |
26 | 4 | 135 | 132 (0.6) | 3 (0.3) | 0.4 (0.13–1.28) | 0.123 |
27 | 14 | 94 | 93 (0.4) | 1 (0.1) | 0.26 (0.04–1.87) | 0.18 |
28 | 6A | 93 | 88 (0.4) | 5 (0.5) | 1.34 (0.52–3.45) | 0.538 |
29 | 6B | 90 | 88 (0.4) | 2 (0.2) | 0.54 (0.13–0.13) | 0.397 |
30 | 9V | 81 | 80 (0.4) | 1 (0.1) | 0.31 (0.04–2.25) | 0.245 |
31 | 23F | 60 | 57 (0.3) | 3 (0.3) | 1.24 (0.38–4.08) | 0.722 |
32 | 18C | 55 | 51 (0.2) | 4 (0.4) | 1.23 (0.43–3.52) | 0.701 |
33 |
21 |
51 |
47 (0.2) |
4 (0.4) |
0.8 (0.28–2.3) |
0.683 |
*Values were adjusted for age and year of diagnosis. Only serotypes responsible for >50 cases of invasive pneumococcal disease were included. Serotypes of decreased odds (decreased aORs with significant p values) are indicated in light gray, and serotypes of increased odds (increased aORs and significant p values) are indicated in dark gray. aOR, adjusted odds ratio. †Because of multiple comparisons, a p value of <0.01 was considered significant. |